Meibomian gland function improvement

Meibomian gland function improvement is not a molecular target but rather a therapeutic goal referring to the restoration or enhancement of the physiological activity of the meibomian glands. These glands are specialized sebaceous glands located along the eyelid margins that secrete lipid-rich meibum essential for maintaining tear film stability and preventing evaporative dry eye disease. Dysfunction can result from age-related degeneration—linked to stem cell exhaustion and altered signaling pathways like hedgehog (Hh) and epidermal growth factor receptor (EGFR)—or from mechanical obstruction due to hyperkeratinization or chronic inflammation. Current interventions focus on physical therapies such as thermal pulsation systems (e.g., LipiFlow), mechanical expression techniques, light-based therapies like intense pulsed light (IPL), and emerging approaches targeting underlying cellular mechanisms. There is no single molecule or receptor named "Meibomian gland function improvement," so this entry does not correspond to a canonical drug target but rather describes a complex tissue-level process involving multiple biological pathways[1][2][3][4].

Other names

Meibomian gland functionMeibomian gland improvementMGD improvementmeibum secretion enhancement

Mechanical clearance of ductal obstruction via heat and pressure to restore lipid flow[1][3]. Stimulation of stem cell activity in the glands via modulation of signaling pathways such as hedgehog and EGFR[2]. Reduction of inflammation through vascular effects and decreased proinflammatory mediators with IPL therapy[4].